Trade Alimera Sciences, Inc. - ALIM CFD
Add to favourite- Summary
- Historical Data
Spread | 0.39 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02629% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004068% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5.00% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 5.4 |
Open | 5.4 |
1-Year Change | 58.82% |
Day's Range | 5.38 - 5.4 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Jul 25, 2024 | 5.39 | 0.00 | 0.00% | 5.39 | 5.40 | 5.38 |
Jul 24, 2024 | 5.40 | 0.01 | 0.19% | 5.39 | 5.40 | 5.38 |
Jul 23, 2024 | 5.40 | 0.02 | 0.37% | 5.38 | 5.40 | 5.38 |
Jul 22, 2024 | 5.38 | 0.00 | 0.00% | 5.38 | 5.38 | 5.37 |
Jul 19, 2024 | 5.37 | -0.01 | -0.19% | 5.38 | 5.38 | 5.37 |
Jul 18, 2024 | 5.38 | 0.00 | 0.00% | 5.38 | 5.39 | 5.38 |
Jul 17, 2024 | 5.37 | 0.00 | 0.00% | 5.37 | 5.39 | 5.37 |
Jul 16, 2024 | 5.38 | 0.00 | 0.00% | 5.38 | 5.40 | 5.37 |
Jul 15, 2024 | 5.37 | -0.03 | -0.56% | 5.40 | 5.41 | 5.37 |
Jul 12, 2024 | 5.40 | 0.03 | 0.56% | 5.37 | 5.40 | 5.37 |
Jul 11, 2024 | 5.37 | -0.01 | -0.19% | 5.38 | 5.40 | 5.37 |
Jul 10, 2024 | 5.37 | 0.03 | 0.56% | 5.34 | 5.39 | 5.34 |
Jul 9, 2024 | 5.34 | 0.00 | 0.00% | 5.34 | 5.35 | 5.33 |
Jul 8, 2024 | 5.34 | 0.00 | 0.00% | 5.34 | 5.37 | 5.34 |
Jul 5, 2024 | 5.33 | 0.00 | 0.00% | 5.33 | 5.35 | 5.33 |
Jul 3, 2024 | 5.34 | 0.01 | 0.19% | 5.33 | 5.34 | 5.33 |
Jul 2, 2024 | 5.33 | 0.00 | 0.00% | 5.33 | 5.34 | 5.33 |
Jul 1, 2024 | 5.33 | -0.02 | -0.37% | 5.35 | 5.35 | 5.33 |
Jun 28, 2024 | 5.34 | 0.00 | 0.00% | 5.34 | 5.35 | 5.34 |
Jun 27, 2024 | 5.33 | 0.00 | 0.00% | 5.33 | 5.34 | 5.33 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Alimera Sciences, Inc. Company profile
About Alimera Sciences Inc
Alimera Sciences, Inc. is a pharmaceutical company. The Company is engaged in commercialization and development of prescription ophthalmic pharmaceuticals. It focuses on diseases affecting the back of the eye or retina. The Company’s commercial product, ILUVIEN, is an intravitreal implant, which treats patients by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. It is engaged in developing for the treatment of diabetic macular edema (DME). DME is a disease of retina that affects individuals with diabetes and can lead to severe vision loss and blindness. ILUVIEN can also be used to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). The Company commercially market ILUVIEN directly in the United States, Germany, United Kingdom, Portugal, and Ireland.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Alimera Sciences Inc revenues increased 16% to $59M. Net loss decreased 18% to $4.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects DEPRECIATION AND AMORTIZATION decrease of 4% to $2.6M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.04 to -$0.66.
Equity composition
Common Stock $.01 Par, 05/11, 100M auth., 31,348,197 issd. IPO:TBA. Insider owns 2.06%.
Industry: | Biopharmaceuticals |
Ste 290
6120 Windward Parkway
ALPHARETTA
GEORGIA 30005
US
News
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024ECB preview: lack of new data sees markets expecting a hold
Markets expect the ECB to keep rates unchanged in July but expectations for a September cut rise
13:13, 18 July 2024What is an IPO and how does it work?
Learn about what an IPO is, why they are important, and how they work.
07:19, 10 July 2024What are the biggest stock exchanges worldwide?
Discover the largest stock exchanges in the world by market capitalisation, including the Nasdaq Stock Market, the New York Stock Exchange and the London Stock Exchange.
12:44, 9 July 2024Top ETFs
ETFs, or exchange-traded funds, offer traders a versatile gateway into the financial markets.
16:23, 8 July 2024Lloyds forecast: will Lloyds share price return to £1? Third party data forecast
What’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
14:00, 8 July 2024RBNZ Preview: OCR expected to remain unchanged as central bank focuses on inflation
The Reserve Bank of New Zealand meets on Wednesday, July 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
13:25, 8 July 2024People also watch
Still looking for a broker you can trust?
Join the 630,000+ traders worldwide that chose to trade with Capital.com